1. Introduction
Retinal
pigment epithelium (RPE) cells play an important role in the development of
proliferative vitreoretinopathy (PVR). This isan abnormal repair
process caused by failed retinal surgery for retinal detachment or serious ocular trauma [1]. During PVR, the surface of the nerve retina
forms a fibrous membrane due to inflammation and wound healing, resulting in
structural deformation of the
retina. The fibrous membranes mainly
include RPE cells, macrophages, myofibroblast-like cells and
glial cells [2]. The fibroblast-like cells are derived from RPE
cells via epithelial to mesenchymal transition (EMT) and are
the underlying cause of PVR [3, 4, 5]. Mature
RPE cells are mitotically quiescent under normal physiological
conditions. However, various growth factors and cytokines are released from the
serum when the blood-retinal barrier is damaged, thereby inducing RPE cells to
enter the EMT process [6]. The essential growth factors and
cytokines are primarily composed of transforming growth factor
(TGF-), fibroblast growth factors (FGF), insulin-like growth
factors (IGF), platelet-derived growth factors (PDGF), epidermal growth factor
(EGF), tumor necrosis factor alpha (TNF-), interleukin-1
(IL-1), IL-6 and IL-8 [7]. These
factors cause the cells to acquire mesenchymal phenotypes with enhanced
proliferation, migration, and invasion capabilities. TGF-2 is the
major regulator of EMT in vitro, with numerous investigators confirming
that it induces EMT in RPE cells [8, 9, 10].
Moreover, ARPE-19 cells exhibit enhanced migratory capacity and increased expression of -smooth muscle actin (-SMA)
in response to TGF-2 treatment [11, 12]. Although
molecular targets of the EMT process have been described, other key factors in
the EMT of RPE cells remain to be
elucidated. These include RNA methylation, which may play crucial roles in EMT
development.
N-methyladenosine (mA) is an abundant, ubiquitous and conserved modification of transcripts
in higher eukaryotes that participates in gene regulation through multiple mRNA
processes [13, 14]. It is a dynamic and reversible
modification process in which mRNA is modified by methyltransferases (including
METTL3, METTL14, METTL16, WTAP, RBM15, RBM15B and KIAA1429), reversed by demethylases (including FTO and
ALKBH5), and recognized by mA binding proteins
(including YTHDC1-2, YTHDF1-3, IGF2BP1-3 and HNRNPA2B1)
[14]. Substantial evidence shows that mA methylation participates in the
control of RNA transcription [15], processing [16], splicing [17, 18],
degradation [19, 20] and translation [21, 22]. Studies have also shown that mA may
have different roles in different cell types. For example, high METTL3 expression
and high mA levels facilitate EMT in lung cancer cells [23], suggesting
that hypermethylation is positively correlated with EMT. However, high ALKBH5
expression and low mA levels promote the development of EMT in
glioblastoma, indicating that hypomethylation is positively correlated with EMT
in these cells [24]. Therefore, mA
modifications may have multiple roles in EMT and complex
regulatory networks that involve diverse target genes. mA methylation has
been extensively studied in various tumor cell types, but less in
retina-associated cells. Increased METTL3 has been reported to reduce
apoptosis and pyroptosis triggered by high glucose and inhibit RPE cell
proliferation [25]. METTL3
expression is reduced in PVR membranes and RPE cells undergoing EMT,
with further studies revealing the Wnt/-catenin
signaling pathway plays a role in the inhibition of EMT by METTL3 [26]. In addition, METTL14 participates in regulating the
methylation of microtubule-associated protein (MAP)2, leading to an imbalance in neuronal differentiation (NEUROD1) and affecting the
activity of RPE cells [27].
Transcriptome-wide
mA modifications have rarely been described in RPE cells,
and the connection between mA
modifications and EMT is not fully
understood. Here, RNA-seq and MeRIP-seq
were performed to analyze the effects of TGF-2 treatment on mRNA
expression and mA modification respectively in RPE cells. This allowed us to analyze the profile of mA methylation
and explore the mechanism by which mA methylation regulates EMT in RPE
cells.
2. Materials and Methods
2.1 Cell Lines and Culture Conditions
Human ARPE-19 cells were purchased from ATCC (CRL-2302, Manassas, VA, USA) and
routinely grown in DMEM medium (Solaibio,
12100, Beijing, China) containing 100 U/mL penicillin, 100 µg/mL
streptomycin, and 10% fetal bovine serum (Gibco, 10099141C, Carlsbad, CA, USA). After the cells adhered, the medium was
replaced with fresh DMEM medium (1% FBS) containing double antibiotics. No
recombinant protein was added to the control group, whereas the TGF-2
group was treated with 20 ng/mL TGF-2
(MedChemExpress, P61812, Monmouth Junction, NJ, USA). Cells in each group were cultured
for 72 hours, and three parallel samples were prepared for each group. The ARPE-19 cells used in this study have been identified by short tandem repeat sequence (STR) analysis and mycoplasma testing was performed.
2.2 Isolation of Total RNA
The extraction of total intracellular RNA
was performed using TRIzol reagent
(Invitrogen, 15596026, Carlsbad, CA, USA)
as previously described [28]. The extracted
RNA was digested with DNase I (Takara,
2270A, Tokyo, Japan). After the quality, integrity and concentration of the total
RNA had been determined, it was sent to Wuhan Seqhealth Technology (Wuhan, China) for sequencing analysis.
2.3 Library Construction and Sequencing
2 µg of total RNA was used for RNA-seq and 50
µg for MeRIP-seq. Polyadenylated RNA was enriched using
Oligo d(T) beads (VAHTS, N401-01, Nanjing, China). The mRNAs were broken into
100–200 nt fragments by 20 mM ZnCl. Ten percent of the RNA fragments were set
as the input group, while the rest were set as the IP group for
immunoprecipitation with mA antibody (Synaptic Systems,
202203, Gottingen,
German). The library was constructed using the KC-Digital Stranded mRNA
Library Prep Kit (Seqhealth, DR08502, Wuhan, China), and the library products
were then sequenced on a Novaseq 6000 sequencer (Illumina) [29]. The raw sequencing data were uploaded to
the NCBI SRA database (SRA accession: SRP422412, Bioproject: PRJNA934747).
2.4 Analysis of Sequencing Data
The raw data were analyzed for quality
with FastQC (version 0.11.5,
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and filtered with
Trimmomatic (version 0.36,
http://www.usadellab.org/cms/index.php?page=trimmomatic) [30]. Clean reads were
clustered by UMI tools (version 1.0, default parameters,
https://gitHub.com/CGATOxford/UMI-tools) and each sub-cluster was aligned
multiple times to eliminate biases and errors [31]. Next, they were aligned with
the Homo sapiens genome assembly GRCh38.p13 using STAR software (version 2.5.3a,
default parameters, https://github.com/alexdobin/STAR). RSeQC (version 2.6,
https://rseqc.sourceforge.net/) was used to assess the distribution, uniformity
of coverage and strand specificity of mapped reads [32]. exomePeak (version 3.8,
https://bioconductor.org/packages/3.8/bioc/html/exomePeak.html) was used to
predict high-intensity and high-resolution mA peaks (peak calling), which were
further annotated using bedtools (version 2.25.0,
https://bedtools.readthedocs.io/en/latest/index.html) [33]. Motif analysis was
performed by Homer (version 4.10, http://homer.ucsd.edu/homer/index.html) to
obtain enriched motifs. deepTools (version 2.4.1,
http://deeptools.ie-freiburg.mpg.de) was applied to analyze the distribution of
mA peaks in each functional region of all transcripts, while bedtools was used
to analyze the distribution of mA peaks on the corresponding chromosome [34, 35].
The reads of all genes annotated in the genome were calculated by featureCounts
(version 1.5.1, http://subread.sourceforge.net). The RPKM value served as a
measure of gene expression and was calculated using the formula shown below.
Differentially expressed genes (DEGs) and differentially methylated genes (DMGs)
between the two experimental groups were screened by the edgeR package (version
3.12.1, http://bioconductor.org/packages/3.2/bioc/html/edgeR.html) with p-value
0.05 and fold change 1.5 [36].
2.5 Enrichment Analysis and Graphics Production
Gene
ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses were performed using Omicshare tools to
determine the enrichment pathways for DEGs and DMGs. A p-value
0.05 indicated statistical significance. PCA and volcano graphs were prepared
by inputting all read counts for each sample, while the nine-quadrant graph was
plotted by inputting the fold change of the DEGs and DMGs. These were performed by Omicshare tools set at the default
parameters.
2.6 Determination of Total Intracellular mA Levels
Total mA
methylation was measured using an mA methylation
quantification kit (EpiGentek, P-9005, Farmingdale, NY, USA)
and 300 ng of total RNA per reaction. Both
negative and positive RNA controls were provided with the kit. The absorbance of
each sample at 450 nm was measured with a
spectrophotometer (Thermo Scientific, Waltham, MA, USA), and
the percentage of mA in the total RNA was calculated [37]. Two replicate wells were analyzed for each sample and the
experiments were repeated three times.
2.7 Real-Time Quantitative PCR (qRT-PCR)
qRT-PCR was performed to verify the level of mRNA as previously
described [28]. cDNA
was synthesized using a Reverse Transcription Kit (Takara,
RR047A, Tokyo, Japan) and qRT-PCR was performed using a StepOnePlus PCR System with TB Green reagent
(Takara, RR820A, Tokyo, Japan). The
relative mRNA levels of target genes were calculated using the 2 algorithm, with the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene used as the reference
gene.
The
primer sequences are listed in Supplementary Table 1.
2.8 Statistical Analysis
Three replicates were set for sequencing, mA
quantitative assay and qRT-PCR. SPSS
software (version 21.0, IBM Corp., Armonk, NY, USA) was used for statistical
analysis, with differences between the control and TGF-2 groups
identified by the student’s t-test. A p-value 0.05
indicated statistical significance.
3. Results
3.1 Analysis of DEGs Induced by TGF-2
Fig. 1A shows the gene expression
clustering map for each group obtained after RNA-seq analysis. To identify TGF-2-induced changes
at mRNA levels, a fold change 1.5 and
p-value 0.05 were used as the threshold for DEGs. As shown in Fig. 1B,C, 929 DEGs were
identified, of which 581 genes showed
increased expression and 348 genes showed decreased expression
(Supplementary Table 2). Heatmap
analysis showed consistency in the gene expression differences observed for the
three replicate samples (Fig. 1D).
Fig. 1.
Analysis of DEGs induced by TGF-2 in ARPE-19 cells.
(A) PCA clustering map of the gene expression profile in each group. (B) Volcano
plot analysis of DEGs. Blue dots represent down-regulated genes, grey dots
represent genes with no difference in expression, and red dots represent
up-regulated genes. (C) Number of DEGs with increased or
decreased expression. (D) Heatmap analysis of DEGs. Red indicates hyper-expressed
genes and blue indicates hypo-expressed genes. (E) GO enrichment analysis of
DEGs. (F) KEGG enrichment analysis of DEGs. The dot size indicates the number of
genes enriched, and the dot color indicates significant enrichment.
GO enrichment analysis revealed the DEGs were primarily related to cell
division, the cell cycle, nuclear division, extracellular matrix organization and
structural constituent, collagen-containing extracellular matrix, and chromosome
segregation (Fig. 1E). KEGG analysis showed the DEGs were involved in the cell
cycle, focal adhesion, ECM-receptor interaction, protein digestion and
absorption, PI3K-Akt signaling, p53 signaling, and the AGE-RAGE signaling pathway
(Fig. 1F).
3.2 Global mA Modification Patterns in RPE Cells
We
next performed transcriptome-wide MeRIP-seq in the control and
TGF-2-treated groups in order to explore the modification of mA
methylation in RPE cells. As shown in Fig. 2, 10,025 mA
peaks were found in the control group and 10,156 in the TGF-2 group, with
8968 overlapping peaks between the two groups (Supplementary Tables
3,4). Compared with the control group, there were 1188 extra peaks and 1057
missing peaks in the TGF-2 group (Fig. 2A). After annotating the peaks,
7626 genes were found to
be mA methylated in the control group, 7685 genes were mA methylated
in the TGF-2 group, and 7183 genes were in the intersection between the
two groups (Fig. 2B). Moreover, mA
methylation frequently occurred within RRACH motifs (Fig. 2C), revealing the
mA consensus motif in RPE cells.
Fig. 2.
mA modification patterns in ARPE-19 cells. (A) Venn analysis of mA
peaks in the control and TGF-2 groups. (B) Venn
analysis of genes modified by mA methylation in the control and TGF-2 groups. (C)
Conserved mA consensus motif in the control and TGF-2 groups. (D)
Distribution of mA methylation at different sites in transcripts. (E)
Distribution of mA peaks in each functional region of genes. 5′UTR,
5′ untranslated region; CDS, coding sequence; 3′UTR, 3′ untranslated
region; ncDNA-T, transcripts of noncoding DNA. (F) Distribution of mA
methylation in transcripts from different chromosomes. MT represents
mitochondrial chromosome.
TGF-2 did not
affect the preference for mA-modified regions, which were enriched near
stop codons (Fig. 2D). mA methylation in the control and TGF-2 groups was
enriched in the CDS, introns and 3′UTR regions of transcripts, with
proportions of 23.62%/23.64%, 48.53%/47.83, and 23.66%/24.44%, respectively
(Fig. 2E). By counting the
number of mA peaks in ARPE-19 cells, it was discovered that mA
modifications occurred in transcripts derived from each
chromosome. Among them,
the number of mA peaks in transcripts
from chromosome 1 was 1626 and 1651 in the control group and TGF-2
group, respectively; while chromosome Y was
no more than 10 (Fig. 2F). After normalization of chromosome length, we found
that mA peaks were the highest on mitochondrial chromosome, followed by
chromosome 19, and the smallest on chromosome Y (Supplementary Fig. 1).
3.3 Analysis of DMGs Induced by
TGF-2
To
evaluate the effect of TGF-2 treatment at the mA methylation level
of individual genes, we set fold change 1.5 and
p-value 0.05 to define DMGs. Only 9 genes were found to contain
hypermethylated peaks, whereas 7325 genes
contained hypomethylated peaks (Fig. 3A, Supplementary Table 5). Table 1
lists the top five genes with hypermethylated peaks (TRO, SLF1,
RBM18, MIEF2, CCNF) and the top five genes with
hypomethylated peaks (SMIM10L2B, PFKP, TTLL11,
RBMS3, BDKRB2). These genes are involved in cell adhesion,
regulation of cell cycle, RNA binding and the bradykinin system. DMGs were present on each
chromosome, with 754 on chromosome 1 and 5 on chromosome Y (Fig. 3B). According
to the normalization of chromosome length, the number of DMGs was the highest on
mitochondrial chromosome and the smallest on chromosome Y (Supplementary
Fig. 2).
Fig. 3.
Analysis of DMGs induced by TGF-2 in ARPE-19 cells.
(A) Number of genes with hypermethylated or hypomethylated peaks. (B)
Distribution of DMGs on different chromosomes. (C) GO enrichment analysis of
DMGs. (D) KEGG enrichment analysis of DMGs.
Table 1.Top five genes with hypermethylated peaks and top five genes
with hypomethylated peaks.
Gene ID |
Gene description |
Chromosome |
Start |
End |
logFC |
p-value |
Annotation |
TRO |
Trophinin, mediates cell adhesion. |
X |
54930557 |
54930632 |
3.1463 |
0.0211 |
CDS |
SLF1 |
Smc5/6 localization factor 1, involved in DNA repair. |
5 |
94694906 |
94695031 |
1.6002 |
0.0231 |
CDS |
RBM18 |
RNA-binding motif protein 18. |
9 |
122238796 |
122239021 |
1.1276 |
0.0322 |
3′UTR |
MIEF2 |
Mitochondrial elongation factor 2, regulates mitochondrial morphology. |
17 |
18265639 |
18265689 |
1.1256 |
0.0094 |
3′UTR |
CCNF |
Cyclin-F, is involved in the regulation of cell cycle and ubiquitination. |
16 |
2457725 |
2457850 |
1.0333 |
0.0055 |
3′UTR |
SMIM10L2B |
Small integral membrane protein 10-like protein 2B. |
X |
135097034 |
135097084 |
–3.2745 |
0 |
3′UTR |
PFKP |
Phosphofructokinase, participates in glycolysis. |
10 |
3066332 |
3066407 |
–2.8447 |
0.0014 |
5′UTR |
TTLL11 |
Tubulin polyglutamylase TTLL11. |
9 |
121989411 |
121989461 |
–2.7538 |
0.0144 |
CDS |
RBMS3 |
RNA binding motif single stranded interacting protein 3. |
3 |
30004611 |
30004661 |
–2.7343 |
0.0002 |
3′UTR |
BDKRB2 |
B2 bradykinin receptor, participates in activating the phosphatidylinositol-calcium second messenger system. |
14 |
96242121 |
96242296 |
–2.6528 |
0.0001 |
3′UTR |
GO enrichment analysis revealed the DMGs were associated with the metabolic
process and RNA binding (Fig. 3C). KGEE analysis found the
DMGs were mainly enriched in cell junction processes (including adherens
junction, tight junction and focal adhesion), the RNA processing pathway
(including spliceosome and RNA transport), apoptosis, regulation of actin
cytoskeleton, and signaling pathways for PI3K-Akt, mTOR, MAPK and AMPK (Fig. 3D).
3.4 Conjoint Analysis of RNA-seq and MeRIP-seq
Conjoint
analysis of DEGs and DMGs was performed to identify genes with altered mRNA and mA modification. As shown in Fig. 4A, one gene showed
up-regulated mRNA and hypermethylated peaks, 215 genes had up-regulated mRNA and
hypomethylated peaks, and 75 genes had down-regulated mRNA and hypomethylated
peaks. Venn diagram analysis showed that 290 genes were altered at the mA
and RNA levels (Fig. 4B, Supplementary Table 6). Comparing Fig. 4A,B,
the CCNF gene was found to be up-regulated at the
transcriptional level, but contained both hypermethylated and hypomethylated
peaks.
Fig. 4.
Conjoint analysis of DEGs and DMGs. (A) Nine-quadrant plot of
DEGs and DMGs. The abscissa represents DMGs and the ordinate represents DEGs. Red
dots represent genes up-regulated at the mRNA and mA levels, yellow dots
represent genes up-regulated at the mRNA level and down-regulated at the mA
level, and green dots represent genes down-regulated at both the mRNA and
mA levels. (B) Venn diagram of DEGs and
DMGs. The p-value is the
hypergeometric distribution, and all genes detected by
sequencing was set as the total number. (C) GO enrichment analysis of genes with
altered mRNA level and mA modification. (D) KEGG enrichment analysis of
genes with altered mRNA level and mA modification.
GO enrichment analysis revealed the conjoint genes were associated with cell
division, the cell cycle, chromosome segregation, and the microtubule
cytoskeleton (Fig. 4C). KEGG enrichment analysis showed the conjoint genes were
related to the cell cycle, apoptosis, focal adhesion, ECM-receptor interaction,
protein digestion and absorption, and the signaling pathways for AGE-RAGE,
PI3K-Akt, cGMP-PKG, and p53 (Fig. 4D).
3.5 Analysis of Conjoint Genes and EMT-Related Genes
To
investigate the connection between mA methylation and EMT, we screened for
EMT-related genes that showed changes at both mA and mRNA levels after
TGF-2 induction. We retrieved 314 EMT-related genes
through a literature review (Supplementary Table 7) [38, 39]. By
cross-matching 290 conjoint genes with 314 EMT-related genes, 12 EMT-related
genes were found to be altered at both the mRNA and mA levels (Fig. 5A), including CALD1, CDH2, FN1, MMP2,
SPARC, KRT7, CLDN3, ELF3, FGF1,
LOXL2, SHROOM3, and TGFBI (Table 2). All 12 genes were up-regulated at the
transcriptional level and hypomethylated at the mA
level, speculating that EMT gene expression may be regulated
by mA methylation in RPE cells.
Fig. 5.
Validation of EMT-related gene expression in ARPE-19 cells. (A)
Overlap between DMGs-DEGs and EMT-related genes. (B) Total mA level in the
control and TGF-2 groups. (C) qRT-PCR validation of the mRNA levels for
EMT-related genes. Asterisks represent statistical significance
(*p-value 0.05, t test).
Table 2.EMT-related genes with increased mRNA level and mA
hypomethylation.
Gene ID |
Gene Description |
mA level |
logFC (mA) |
mA sites |
mRNA level |
logFC (mRNA) |
CALD1 |
Caldesmon 1, participates in smooth muscle contraction. |
Down |
–0.8467 |
5′UTR |
Up |
0.6046 |
CDH2 |
Cadherin 2, is involved in homotypic cell adhesion. |
Down |
–0.8173 |
CDS |
Up |
0.6275 |
FN1 |
Fibronectin 1, mediates cell adhesion and cell motility. |
Down |
–0.7624 |
CDS |
Up |
0.9369 |
MMP2 |
Matrix metallopeptidase 2, participates in vasculature remodeling, cell invasion and inflammation. |
Down |
–0.7004 |
3′UTR |
Up |
1.7231 |
SPARC |
Secreted protein acidic and cysteine rich, affects cell growth. |
Down |
–0.7842 |
5′UTR |
Up |
0.6247 |
KRT7 |
Keratin 7, facilitates DNA synthesis. |
Down |
–0.7546 |
CDS |
Up |
0.8805 |
CLDN3 |
Claudin-3, participates in tight junction. |
Down |
–1.1295 |
3′UTR |
Up |
0.6724 |
ELF3 |
E74 like ETS transcription factor 3, transcriptional activator. |
Down |
–0.8627 |
3′UTR |
Up |
1.2989 |
FGF1 |
Fibroblast growth factor 1, regulates cell division, differentiation, migration and angiogenesis. |
Down |
–0.9726 |
3′UTR |
Up |
1.2966 |
LOXL2 |
Lysyl oxidase like 2, interacts with SNAI1 and inhibits CDH1 expression. |
Down |
–0.7532 |
3′UTR |
Up |
0.6011 |
SHROOM3 |
Shroom family member 3, promotes apicobasal cell elongation and regulates cell morphology. |
Down |
–1.4456 |
CDS |
Up |
0.5912 |
TGFBI |
TGF- induced protein, participates in cell adhesion. |
Down |
–0.6216 |
3′UTR |
Up |
0.9588 |
The
total intracellular mA level was reduced in RPE cells following treatment
with TGF-2, as compared to untreated cells (Fig. 5B). In addition, qRT-PCR of the 12 EMT-related genes confirmed that
CALD1, CDH2, FN1, MMP2, SPARC,
FGF1, LOXL2, SHROOM3, and TGFBI were
significantly up-regulated (Fig. 5C).
4. Discussion
mA methylation is an extensive intracellular RNA
modification and part of a complex regulatory network that affects gene
expression in various physiological conditions [14]. As mentioned above, the EMT process in RPE cells is crucial for
the formation of fibrous membranes. TGF-2 is an important EMT-inducing
factor. To investigate the connection between mA methylation and EMT in RPE
cells, we performed transcriptome-wide
mA-modified mapping of TGF-2-induced RPE cells. Consistent with
previous studies, mA modification was prevalent in RPE
cells. MeRIP-seq revealed 10,025 mA peaks in the control group and 10,156
peaks in the TGF-2 group, with mA modifications present in
transcripts from each chromosome (Fig. 2A,F). mA methylation is conserved
at modification sites in different regions of transcripts,
preferentially near stop codons and within 3′UTR [40]. Furthermore, 35% of mA modifications are located in the
CDS region, where they can positively regulate translation by resolving mRNA
secondary structure [41]. The present study found that mA modifications were abundant
in the CDS, introns and 3′UTR regions of transcripts, as well as being
centered around stop codons (Fig. 2D,E). The METTL3-METTL14
complex preferentially recognizes mA methylation sites in RRACH motifs in
mammalian cells [42]. Consistent with this, our study also confirmed that mA
methylation identified the RRACH motif in RPE cells (Fig. 2C). These results
indicate that mA methylation is a prevalent and conserved RNA modification
in RPE cells.
Comparison
of the methylation changes between control and
TGF-2 groups identified 7334 DMGs,
of which only 9 genes (0.12%) had
hypermethylated mA peaks (Fig. 3A). In accordance with
this observation, the total mA methylation level of intracellular mRNA
decreased after treatment with TGF-2 (Fig. 5B). Thus, we speculating that mA methylation is negatively correlated with the EMT process in RPE
cells. KEGG analysis found the DMGs were
enriched in adherens
junction, tight junction, focal adhesion, and regulation of actin
cytoskeleton (Fig. 3D). These affect epithelial cell polarity [43], cell
migration [44], and cell homeostasis [45]. The DMG-enriched pathways include PI3K/Akt signaling,
which mediates cell cycle, cell growth, apoptosis, metabolism, angiogenesis,
migration, differentiation and EMT [46]. mTOR signaling also participates in the regulation of EMT by altering the protein
kinase C (PKC) phosphorylation level and by directly phosphorylating and
activating Akt [47]. These observations
suggest a potential relationship between mA methylation and EMT in RPE
cells.
Conjoint analysis of DMGs and DEGs
revealed that 290 genes were simultaneously altered at the mA and RNA
levels. These conjoint genes were enriched in ECM-receptor
interactions, AGE-RAGE signaling, PI3K-Akt signaling, cGMP-PKG signaling, and the p53 signaling pathway
(Fig. 4B,D). ECM-receptor interactions have
profound effects on major cellular programs including growth, differentiation,
migration and survival, and have been associated with the EMT process in RPE
cells [48]. AGE-RAGE signaling enhances
NF-kB signaling, stimulates the generation
of reactive oxygen species, and accelerates the EMT process induced by
TGF- [49]. cGMP/PKG signaling is
also involved in EMT. For example, atrial natriuretic peptide inhibits the EMT
process through the cGMP/PKG pathway [50]. In addition,
TGF-1 has a profibrotic effect by inhibiting soluble guanylate
cyclase-cGMP-PKG signaling in systemic sclerosis [51]. p53 signaling is also
closely related to the EMT process, with wild-type p53 negatively regulating EMT
initiation and metastasis, whereas mutant p53 promotes EMT and metastasis [52].
These findings suggest that mA methylation could regulate
EMT through multiple signaling pathways.
Twelve EMT-related genes (CALD1,
CDH2, FN1, MMP2,
SPARC, KRT7, CLDN3, ELF3, FGF1, LOXL2,
SHROOM3, TGFBI) showed both increased mRNA
levels and hypomethylation after TGF-2 treatment (Table 2). CALD1, CDH2, FN1,
MMP2 and SPARC are known to be highly expressed in EMT [38],
and most can be used as prognostic biomarkers for various cancers. Among them, fibronectin (FN) encoded by
FN1 is essential in the EMT process and fibrosis. Massive deposition of
FN, a component of the extracellular matrix, is known to promote tumor cell
growth, migration, invasion and angiogenesis [53]. Furthermore, FN mediates the initial process of fibrous membrane formation,
and intravitreal FN concentrations increase with the clinical stage of PVR evolution [54]. The expression and
phosphorylation of caldesmon, encoded by CALD1, is up-regulated after
TGF- treatment, further increasing the number and size of focal
adhesions and cell contractility [55]. N-cadherin encoded by
CDH2 is ubiquitous in non-epithelial tissues and acts as a biomarker of
cells undergoing EMT, as well as mediating cell survival and migration [56]. MMP2
participates in the degradation of collagen and basement membrane and is associated with cell migration [57]. Variants of the
matricellular glycoprotein SPARC play a crucial role in the regulation of EMT
induced by TGF- [58]. The EMT-related genes KRT7, FGF1, LOXL2,
SHROOM3 and TGFBI encode for keratin 7, a transcription factor,
a growth factor, lysyl oxidase, a shroom family member and TGF- induced
protein, respectively. They have been shown to facilitate the EMT program in
various cell types [59, 60, 61, 62, 63]. The two remaining EMT-related genes, CLDN3
and ELF3, act as negative regulators of EMT. CLDN3 is a major structural
component of tight junctions in epithelial cells [64], while ELF3 inhibits EMT by
reducing the expression of ZEB1 [65]. Based
on the observation that CLDN3 and ELF3 mRNA levels were
up-regulated after TGF- treatment, we speculate they may undergo further
regulation at the translational level.
In previous studies,
TGF- treatment was reported to significantly
up-regulate the mA levels of EMT-associated transcription factors such as
Snail, ZEB and JUNB in lung cancer cells and HeLa cells [23, 38]. However, in the present study we found that
mA levels of EMT genes were reduced in RPE cells following
TGF-2-induced EMT, suggesting mA methylation could have opposite
roles during EMT in different cell types. Although
we found potential target genes for mA modification, further in-depth and
systematic studies are required to fully elucidate the regulatory mechanism of
mA. Additional questions
that need to be addressed are whether the regulation of mA on EMT-related
genes occurs pre- or post-transcription, and whether mA is also involved in
regulation at the translational level. Follow up studies
should therefore use molecular techniques to verify the role of mA and to
identify mA readers that play a key role in regulating EMT target genes.
The relationship between mA and EMT also needs further confirmation in
experimental animal models and in clinical specimens before treatments for EMT
can be developed.
The EMT process of RPE
cells plays an important role in the pathogenesis of retinal diseases, such as
PVR and age-related macular degeneration (AMD) [66]. However, the pathogenesis of
EMT is still under investigation, therefore the non-surgical treatment on retinal
diseases is limited at present. In this study, by establishing the EMT model of
RPE cells, we found that the transcripts of 12 EMT-related genes were
hypomethylated, and the total mA level was down-regulated during EMT. In
addition, the mA methyltransferases METTL3 was shown to attenuate EMT [26].
It is speculated that hypermethylation could inhibit EMT in RPE cells. Therefore,
it could be desirable to find a way to increase the intracellular mA level
by some methods to inhibit EMT and treat retinal diseases. For example, small
molecule inhibitors of mA demethylase FTO (FB23 and FB23-2), which have
been shown to play an inhibitory role in the development of leukemia by
inhibiting FTO activity could be considered [67]. Furthermore, two other
inhibitors of FTO, CS1 and CS2, were found to have more potent anti-tumor
efficacy and fewer side effects [68]. Whether these FTO inhibitors can affect the
EMT process by acting on the transcript of EMT-related genes, and whether they
inhibit the development of retinal diseases remains to be revealed.
5. Conclusions
We identified differentially methylated genes and differentially expressed genes
using MeRIP-seq and RNA-seq, respectively, following treatment of RPE cells with
TGF-2, an inducer of EMT. We also provide preliminary results on the
mA modification profile in RPE cells after TGF-2 treatment.
mA modification was found to be widespread and the mA motif was
conserved. Further association analysis identified 12 EMT-related genes that were
altered at both the methylation level and the mRNA level, suggesting they may be
targets of mA methylation that affects EMT.
Availability of Data and Materials
The datasets generated and/or analyzed during the current
study are available in the NCBI SRA repository
(https://www.ncbi.nlm.nih.gov/sra/) with the SRA accession number: SRP422412.
Author Contributions
XiaL designed the research study and provided advice on supervision. XZ and XueL
performed the research. XZ, LL and YZ analyzed the data. FW, RY and MY validated
the data. XZ wrote the manuscript. XZ and XiaL revised the manuscript. All authors
contributed to editorial changes in the manuscript. All authors read and approved
the final manuscript.
Ethics Approval and Consent to Participate
Not applicable.
Acknowledgment
Sequencing was performed by Wuhan Seqhealth Technology. The Omicshare platform
was used to analyze GO enrichment and KEGG enrichment of differential genes.
Funding
This research was funded by National Natural Science Foundation of China, grant
number 81770952 and 81873681; Basic Research Program of Henan Eye Hospital, grant
number 20JCQN005; Natural Science Foundation of Henan Province, grant number
222300420194; Henan Provincial Medical Science and Technology Research Joint
Co-construction Project, grant number LHGJ20210075.
Conflict of Interest
The authors declare no conflict of interest.